Aroa Biosurgery Reported Positive Wound Care Trial

A study showed that the Symphony product improved healing rates for diabetic foot ulcers.

Updated on Oct. 5, 2026 in Diabetes

Bold vector editorial illustration of a woven biological tissue patch, representing medical innovation in wound care technology. — Aroa Biosurgery announced positive clinical trial results for its Symphony wound care product, demonstrating improved healing rates for diabetic foot ulcers. AI Illustration. Upload story photo >

Live Poll

Should healthcare systems prioritize new specialized products for diabetic wound treatment?

Aroa Biosurgery reported positive clinical trial results for its Symphony wound care product. The study found that patients using the product experienced improved healing rates and faster recovery compared to standard care.

Why it matters

These results provide clinical evidence that may support product differentiation and broader adoption in the treatment of diabetic foot ulcers. Improving healing outcomes is critical for patients managing chronic complications associated with diabetes.

A clinical trial of 143 patients across 10 U.S. sites showed a 55% closure rate for Symphony versus 35% for standard care. The mean healing time for the treatment group was 65.4 days, compared to 73.2 days for the control group.

The players

Aroa Biosurgery

A medical technology company headquartered in Auckland, New Zealand, that focuses on regenerative tissue repair products.

The details

The study assessed Wagner Grade 1 and Grade 2 diabetic foot ulcers over a 12-week period. Symphony, which uses extracellular matrix technology and high molecular weight hyaluronic acid, was applied weekly alongside standard care.

The clinical trial duration for wound closure assessment was 12 weeks.

The Big Picture

This study updates the efficacy benchmarks established by the standard care protocols for Wagner Grade 1 and 2 diabetic foot ulcers. The findings mark a potential improvement in therapeutic options for chronic wound management.

For patients suffering from diabetic foot ulcers, this product may offer a more effective path to wound closure and reduced healing times. These results could influence the types of advanced wound care treatments offered by healthcare providers in the future.

The takeaway

Advancements in extracellular matrix technology are providing new ways to address chronic complications in diabetic patients. Patients should consult their wound care specialists to discuss whether emerging treatments align with their specific clinical needs.